Predictive Role of Soluble IL-6R, TNF-R1/2, and Cell Adhesion Molecules Serum Levels in the Preoperative and Adjuvant Therapy in Women with Nonmetastatic Breast Cancer: A Preliminary Study
Journal of Interferon & Cytokine Research · 01.11.2022 · 42 (11) · 557-567
DOI: 10.1089/jir.2022.0092 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Interferon & Cytokine Research, erschienen am 01.11.2022. Verfasst von Weronika Bulska-Będkowska und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Diseases and Oncological Chemotherapy, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Polan…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben.
Abstract (Originalsprache)
Soluble cell adhesion molecules (sCAMs) are involved in the development of neoplastic diseases. sCAMs can block lymphocytes and promote angiogenesis and migration of breast cancer (BC) cells. Interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) enhance metastatic potential via upregulation of CAMs. We assessed soluble interleukin-6 receptor subunit alpha (IL-6Ra), TNF-R1, TNF-R2, E-selectin, P-selectin, VCAM-1, ICAM-1, and EpCAM in 89 women with stage I-III BC and 28 healthy women. Blood samples were obtained at the beginning of neoadjuvant/induction (N = 49) or adjuvant treatment (N = 40), and after 2 months. Surgery revealed complete response in 29.4% of patients, partial response in 67%, and stable disease in 5.9%. Achieving a pathological response was 4 times greater for baseline levels of sIL-6Ra >5.63 ng/mL [odds ratio (OR) = 4.1, 95% confidence interval (CI): 0.8-20.4, P = 0.08] and more than 6 times for soluble tumor necrosis factor receptor 1 (sTNF-R1) ≥ 0.97 ng/mL (OR = 6.2, 95% CI: 1.2-32.3, P < 0.05). Compared with the control group, serum sP-selectin, soluble epithelial cell adhesion molecule (sEpCAM), and sTNF-R2 concentrations were significantly higher in patients who started adjuvant therapy (P < 0.05) and preoperative therapy (P < 0.01). Baseline serum sIL-6Ra concentrations were significantly higher in patients before surgery than in patients after tumor resection (P < 0.05), independent of the follow-up time. The baseline serum soluble receptors of IL-6 (sIL-6R) and TNF-α (sTNF-R1) concentrations have a predictive value for preoperative therapy in patients with BC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Diseases and Oncological Chemotherapy, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland.
- Health Promotion and Obesity Management Unit, Department of Pathophysiology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland.
- Department of Biochemistry, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland.
ORCID-Profile: Weronika Bulska-Będkowska
Zitieren
APA
Bulska-Będkowska, W., Czajka-Francuz, P., Cisoń-Jurek, S., Owczarek, A. J., Francuz, T., & Chudek, J. (2022). Predictive Role of Soluble IL-6R, TNF-R1/2, and Cell Adhesion Molecules Serum Levels in the Preoperative and Adjuvant Therapy in Women with Nonmetastatic Breast Cancer: A Preliminary Study. Journal of Interferon & Cytokine Research, 42(11), 557-567. https://doi.org/10.1089/jir.2022.0092
Vancouver
Bulska-Będkowska W, Czajka-Francuz P, Cisoń-Jurek S, Owczarek AJ, Francuz T, Chudek J. Predictive Role of Soluble IL-6R, TNF-R1/2, and Cell Adhesion Molecules Serum Levels in the Preoperative and Adjuvant Therapy in Women with Nonmetastatic Breast Cancer: A Preliminary Study. Journal of Interferon & Cytokine Research. 2022;42(11):557-567. doi:10.1089/jir.2022.0092
BibTeX
@article{BulskaBdkowska2022,
author = {Bulska-Będkowska, Weronika and Czajka-Francuz, Paulina and Cisoń-Jurek, Sylwia and Owczarek, Aleksander J and Francuz, Tomasz and Chudek, Jerzy},
title = {Predictive Role of Soluble IL-6R, TNF-R1/2, and Cell Adhesion Molecules Serum Levels in the Preoperative and Adjuvant Therapy in Women with Nonmetastatic Breast Cancer: A Preliminary Study},
journal = {Journal of Interferon & Cytokine Research},
year = {2022},
volume = {42},
number = {11},
pages = {557--567},
doi = {10.1089/jir.2022.0092}
}
EUVIMED